Últimas noticias sobre Travel+Leisure (NYSE:TNL) Bolsa

TRAVEL + LEISURE CO

Travel+Leisure

Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.

Travel+Leisure Co

Trainline PLC

Trans-Lux Corp

TNL Mediagene

Citigroup analyst Tyler Radke maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Buy and lowers the price target from $115 to $110.

News

Price Target

Analyst Ratings

DOCU

Citigroup Maintains Buy on Docusign, Lowers Price Target to $110

The bad news for Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and its shareholders continues in 2025, with a highly public feud between CEO Elon Musk and President Donald Trump adding to question marks like demand, <a href="https://www.benzinga.com/news/politics/25/06/45824984/exclusive-trump-can-hurt-elons-businesses-says-tesla-protest-organizer-but-at-this-point-whos-left-to-buy" target="_blank" rel="noopener">brand damage,</a><a href="https://www.benzinga.com/news/politics/25/06/45824984/exclusive-trump-can-hurt-elons-businesses-says-tesla-protest-organizer-but-at-this-point-whos-left-to-buy"> and robotaxis.</a>
A new survey shows whether investors are ready for Tesla to part ways with the dynamic CEO.
What Happened: Tesla stock <a href="https://www.benzinga.com/news/politics/25/06/45821929/trump-vs-musk-president-selling-his-tesla-is-targeting-robotaxis-next">suffered its largest </a>one-day market capitalization decline with a $152 billion drop after Musk's feud with Trump.
The drop continues a highly volatile year for Tesla stock, with rises and falls related to Musk's push into politics and Trump&#8217;s 2024 election win.
While a close friendship between Trump and Musk was once viewed as a catalyst for Tesla&#8217;s stock price to go up, it also led to drops, with Tesla suffering brand damage and seeing protests due to Musk's political push.
A feud between Trump and Musk could send Tesla shares down even more in the future. Benzinga recently polled readers about the electric vehicle company&#8217;s future.
"The battle with Donald Trump could hurt Tesla&#8217;s brand value and image even more as the company looks to recover from a rough year that saw protests and declining sales. Do you think Tesla&#8217;s Board of Directors should replace Musk as CEO?" Benzinga asked.
Here are the results:
<ul class="wp-block-list">
<li>No: 45%</li>
<li>Yes: 38%</li>
<li>Don't Know/Not Sure: 17%</li>
</ul>
The poll found a near majority aren't ready to see Tesla's Board of Directors move on from Musk with 45% saying No. While this was a near-majority, the answer of Yes followed close behind at 38%, with the remaining&nbsp; 17% of readers unsure of where they stood.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: A recent Wall Street Journal report suggested Tesla's board had discussed the possibility of moving <a href="https://www.benzinga.com/news/management/25/05/45155242/elon-musk-out-as-tesla-ceo-in-2025-prediction-markets-put-little-faith-in-wsj-report-here-are-the-top-replacement-picks">on from Musk.</a>
Musk has indicated that his time in the White House is over, and he will be spending significant time helping to shape Tesla&#8217;s future. This coincides with the launch of Robotaxis in Texas this month.
The Tesla CEO has said he plans to be at Tesla for at least<a href="https://www.benzinga.com/markets/equities/25/05/45126370/elon-musk-will-remain-tesla-ceo-for-at-least-5-years-says-dan-ives-as-company-calls-replacement-rumors-absolutely-false"> five more years, </a>which would mean the Board of Directors would have to make a change to get rid of him.
The board may be unwilling to get rid of the person who has meant so much to the company, even with recent controversy and high share price volatility.
Prediction market <a href="https://polymarket.com/event/musk-out-as-tesla-ceo-in-2025?tid=1749487851486">Polymarket </a>currently has a 15% chance that Musk is out as the Tesla CEO In 2025. The odds hit 21% on June 5 as the feud with Trump escalated.
On the prediction market <a href="https://kalshi.com/markets/kxteslaceochange/new-tesla-ceo" target="_blank" rel="noopener">Kalshi</a>, there is a 14% chance that Musk will be out as the Tesla CEO this year. The odds hit 21% on June 6.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 212 adults.
Image created using photos from Shutterstock.

Sports Betting

Management

Exclusives

Trading Ideas

TSLA

EXCLUSIVE: Should Musk Be Fired From Tesla After Trump Feud? 45% Say This In New Poll

WIIM

Micron Technology shares are trading higher after Citigroup maintained its Buy rating on the stock and raised the price target from $110 to $130.

Citigroup analyst Andrew Kaplowitz maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Neutral and raises the price target from $70 to $80.

ATKR

Citigroup Maintains Neutral on Atkore, Raises Price Target to $80

Citigroup analyst Christopher Danely maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Buy and raises the price target from $276 to $285.

AVGO

Citigroup Maintains Buy on Broadcom, Raises Price Target to $285

Boeing shares are trading higher after RBC Capital maintained its Outperform rating and raised the price target from $200 to $230.

A <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">highly public feud </a>between Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk and President Donald Trump took the world by storm last week and sent shares of the electric vehicle company lower.
As the feud continues on, here's a look at where Benzinga readers stand.
What Happened: A <a href="https://www.benzinga.com/news/politics/25/06/45821929/trump-vs-musk-president-selling-his-tesla-is-targeting-robotaxis-next">back-and-forth</a> between Musk and Trump across social media platforms saw the two well-known individuals escalate a feud related to differences on the "Big Beautiful Bill."
The feud comes after Musk left his White House position working for the Department of Government Efficiency to spend more time working on his other companies, such as Tesla.
Benzinga recently asked readers who they side with in the battle, which includes Musk criticizing the new debt the country will take on if the bill that Trump supports is passed by Congress.
"In the feud between Donald Trump and Elon Musk, who are you more likely to publicly support?" Benzinga asked.
Here are the results:
<ul class="wp-block-list">
<li>Neither: 44%</li>
<li>Elon Musk: 25%</li>
<li>Donald Trump: 17%</li>
<li>Both: 14%</li>
</ul>
The poll found that a near majority said they would publicly support neither Trump or Musk in the feud between former friends.
Of the two well-known candidates, Musk received the largest support with 25% of the poll, ranking ahead of Trump at 17%.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45827517/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-68">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Over the weekend, the battle between Musk and Trump minimized some with the Tesla CEO deleting some of his tweets that brought some claims against the current president. Tweets about ending the SpaceX Dragon program were also deleted.
A battle between Trump and Musk over the long run could see many losers, including the country's space program and the launch of robotaxis, with Musk a leader in both sectors and Trump able to slow down progress made by the billionaire.
Tesla stock saw its largest one-day market capitalization drop last week on the heels of the feud. 
Tesla stock trades up 1.61% at $299.72 at publication on Monday versus a 52-week trading range of $167.42 to $488.54. The stock has fallen 15% over the last five days and is down 22% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 259 adults.

Photo: Shutterstock

Entertainment

Politics

Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither

Leverage Shares&#8216; launch of RTXG, the first-ever 2X leveraged ETF tracking defense contractor RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), marks a notable shift in the firm's strategy <a href="https://www.benzinga.com/etfs">beyond tech-focused products</a>. 
The ETF launched trading on June 6, a move away from the issuer&#8217;s typical tech-biased product platform.
Leverage Shares 2X Long RTX Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTXG#NASDAQ">RTXG</a>) arrives as investor interest in military-industrial themes grows. RTXG offers amplified daily exposure to a major defense stock at a low management fee. It also appeals to tactical traders seeking short-term momentum plays tied to geopolitical catalysts. 
The ETF&#8217;s launch underscores the broader expansion of single-stock ETFs into traditionally underrepresented sectors like defense and industrials.
RTXG joins a roster of tactical trading instruments targeting retail and institutional investors looking for sharper exposure to market themes.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/06/45842761/silver-just-shattered-a-14-year-ceiling-could-50-be-next">Silver Just Shattered A 14-Year Ceiling &#8211; Could $50 Be Next?</a>
The fund mirrors RTX&#8217;s daily price fluctuations at 200% leverage, such that a 1% increase (or decrease) in RTX would result in a 2% return (or loss) to RTXG, a high-risk, high-reward trade that is more suitable for short-term trades than for long-term holding.
What distinguishes RTXG in a growingly dense leveraged ETF landscape is its 0.75% management fee, one of the lowest in the group. The action follows Leverage Shares&#8217; doubling its ETF lineup to 16 single-stock funds as part of a wider push to provide additional thematic exposure in defense, energy, and industrials—sectors that often go underrepresented in the leveraged product universe.
The firm attributes its entry into non-tech names as a reaction to changing investor appetite. While RTXG might be attractive to momentum investors speculating on defense outlays or geopolitics tailwinds, advisers warn that leveraged ETFs are best employed with discipline and well-defined exit strategies.
RTX previously did business as Raytheon Technologies.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45841817/us-listed-chinese-stocks-gain-as-us-china-trade-talks-spark-optimism">US Listed Chinese Stocks Gain As US-China Trade Talks Spark Optimism</a></li>
</ul>
Image: Shutterstock

New ETFs

ETFs

RTXG

RTXG ETF Takes Flight With 2X Daily Exposure To Aerospace Giant As Defense Spending Spikes

Citigroup analyst Jason Gursky maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Buy and raises the price target from $245 to $280.

Citigroup Maintains Buy on L3Harris Technologies, Raises Price Target to $280

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is reportedly weighing multiple offers for its Latin American business as it scrambles to recover from a string of corporate stumbles, including a leadership shakeup and a <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reported federal investigation</a>.
The potential sale, involving its Banmedica unit, comes as the company seeks to restore shareholder confidence and streamline operations under new leadership.
In May, UnitedHealth's CEO, Andrew Witty,&nbsp;resigned for personal reasons.&nbsp;Stephen Hemsley, who previously held the CEO title from 2006 to 2017,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">succeeded him</a>. The company also suspended its 2025 outlook.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45624067/unitedhealth-hits-2008-era-oversold-levels-as-citadel-advisors-sells-fisher-buys" rel="noreferrer noopener">UnitedHealth Hits 2008-Era Oversold Levels As Citadel Advisors Sells, Fisher Buys</a>
In an SEC filing on Wednesday, UnitedHealth&nbsp;<a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/731766/000073176625000154/unh-20250602.htm&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">said</a> it canceled the performance-based restricted stock units granted to Witty,
Year to date, UnitedHealth's stock has plunged almost 40%, with the majority coming after the disappointing fourth-<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" rel="noreferrer noopener">quarter 2024 earnings</a>.
After reporting weaker-than-expected earnings and facing allegations of Medicare fraud—currently not formally acknowledged by the Department of Justice—UnitedHealth is <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">shifting its focus</a>.
Reuters notes that the insurance giant has been working to exit Latin America since 2022, but recent developments have heightened the urgency of its plans.
UnitedHealth's aggressive growth strategy under Witty exposed the healthcare giant to mounting regulatory scrutiny, soaring costs, and a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">shifting Medicare landscape</a>.
Hemsley is stepping forward to acknowledge the fallout and chart a new course, promising a comprehensive review of some of the company's most controversial practices.
Citing individuals familiar with the matter, Reuters reported UnitedHealth had received four non-binding bids for Banmedica, which operates in Colombia and Chile. The bids reportedly value the business at approximately $1 billion.
Interested parties include Acon Investments, Patria Investments, Christus Health, and Auna, with the latter exploring a financial partnership to support its offer.
The company aims to set a July deadline for binding proposals for Banmedica, which generates more than $200 million in annual EBITDA.
Banmedica <a target="_blank" href="https://www.financierworldwide.com/fw-news/2018/1/2/unitedhealth-to-acquire-banmdica" rel="noreferrer noopener">was</a> acquired in 2018 as part of UnitedHealth's plan to expand across South America. Then, CEO David Wichmann touted the deal as a foundation for growth for decades. However, financial challenges led the company to reverse.
UnitedHealth previously exited Brazil in late 2023 and Peru earlier this year.
UnitedHealth recorded an $8.3 billion loss tied to its South American operations—$7.1 billion from Brazil and $1.2 billion from Banmedica.
Though Banmedica remains profitable, with over 2.1 million insurance members and about 4 million patient visits annually across its 13 hospitals and 143 medical centers, UnitedHealth now views it as too small to align with its long-term strategic goals.
Price Action: UNH stock is down 0.51% at $301.67 at the last check on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45796533/humana-backs-reforms-to-limit-medicare-advantage-billing-practices" target="_blank" rel="noreferrer noopener">Humana Backs Reforms To Limit Medicare Advantage Billing Practices</a></li>
</ul>
Photo by Ken Wolter via Shutterstock

Large Cap

Health Care

Rumors

Asset Sales

Media

General

UnitedHealth Eyes Retreat From Latin America After $8.3 Billion Loss

Citigroup analyst Jason Gursky maintains Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Buy and raises the price target from $46.5 to $58.

KRMN

Citigroup Maintains Buy on Karman Holdings, Raises Price Target to $58

Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares are trading higher Monday after the company announced it entered into a distribution services agreement <a href="https://www.benzinga.com/pressreleases/25/06/n45834791/citius-oncology-enters-into-distribution-services-agreement-with-cardinal-health">with Cardinal Health</a>.
The Details: Cities entered into a distribution services agreement with Cardinal Health to help provide access to LYMPHIR (denileukin diftitox-cxdl), an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, in support of its anticipated U.S. commercial launch.
Under the agreement, Cardinal will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services. &#8220;This agreement marks a key step forward in our launch readiness efforts,&#8221; said Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals.
&#8220;Cardinal Health&#8217;s proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network.&#8221;
CTXR Price Action: At the time of publication Monday, Citius Pharmaceuticals shares were up 100.9% at $1.73, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiFq8zk8eSNAxXOm4kEHc9sFlAQFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45843490/jm-smucker-likely-to-report-lower-q4-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">JM Smucker Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Image via Shutterstock.

Movers

CTXR

Citius Pharmaceuticals Stock Is Soaring Monday: What's Going On?

Citigroup analyst Jason Gursky maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Buy and raises the price target from $444 to $520.

Citigroup Maintains Buy on Curtiss-Wright, Raises Price Target to $520

Advanced Micro Devices shares are trading higher after Citigroup raised its price target on the stock from $100 to $120.

MSTR

MicroStrategy shares are trading higher after the company announced it acquired another 1,045 BTC For $110.2 million between June 2-June 8.

Arm Holdings shares are trading higher after Benchmark reiterated its Hold rating on the stock.

Dogecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) relatively flat performance over the past week has market commentators speculating about two important liquidation levels <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">for the meme coin</a>.
What Happened: Crypto trader Trader Tardigrade noted that Dogecoin's liquidation heatmap reveals two major liquidity targets above the current price:
<ul class="wp-block-list">
<li>$0.189 with $2.46 billion in liquidity</li>
<li>$0.1995 with $2.14 billion in liquidity</li>
</ul>
These are likely areas market makers will aim for, suggesting upward price potential.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> Liquidation Heatmap shows two significant liquidation levels above the current price. The highest level is at $0.189 with $2.46B in liquidity, and the second is at $0.1995 with $2.14B in liquidity. Market makers are aware of these levels, so you don&#39;t have to worry… <a href="https://t.co/U79beCdfpM">pic.twitter.com/U79beCdfpM</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1932056863702741095?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Hardy <a href="https://x.com/Degen_Hardy/status/1932025566821335307">observed</a> Dogecoin has returned to a strong support zone, potentially setting up a new long opportunity. The chart will be closely monitored over the next few days for confirmation.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45833498/bitcoin-ethereum-xrp-dogecoin-start-the-week-green-ahead-of-us-china-trade-talks">Bitcoin, Ethereum, XRP, Dogecoin Start The Week Green Ahead Of US-China Trade Talks</a>
Why It Matters: Pseudonymous developer PennybagsCX <a href="https://x.com/PennybagsCX/status/1932114088777203906">stated</a> that Dogechain, launched in 2022, is quietly transforming Dogecoin from a meme-based currency into a full-fledged utility ecosystem.
As an EVM-compatible blockchain, Dogechain enables smart contracts and allows DOGE to be bridged and used for transactions across a growing suite of applications. 
This includes gaming dApps, NFT marketplaces, and DeFi protocols like lending, borrowing, and yield farming, all powered by DOGE.
By expanding Dogecoin's use cases beyond simple payments, Dogechain is unlocking new opportunities for holders and helping build a vibrant, utility-driven future for the Doge community.
Coinglass data shows Dogecoin's open interest is up by 1.3% to $1.99 billion, while derivatives trading volume expanded by 25.4% in a single day. 
Options volume and options open interest expanded by 1,829% and 502.9%, respectively.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

What Is Dogecoin's Next Move? Watch These 2 Liquidation Levels, Trader Warns

AAPL

GPRO

Watching GoPro; Shares Spike Higher, Apple Announces 'VisionOS 26 supports native playback of 180-degree, 360-degree, and wide field-of-view content from Insta360, GoPro, and Canon'

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hyperlipidemia on lipid-lowering therapies, including <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">at least a statin</a>.
Hyperlipidemia&nbsp;refers to having high levels of lipids (fats) in the blood, including cholesterol and triglycerides.&nbsp;It&#8217;s a condition that can increase the risk of heart disease and other health problems.&nbsp;
The CORALreef HeFH and CORALreef AddOn trials met their primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful greater reductions in low-density lipoprotein <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45832810/merck-announces-positive-topline-results-from-the-first-two-phase-3-coralreef-trials-evaluating-en" rel="noreferrer noopener">cholesterol (LDL-C) for</a>:
<ul class="wp-block-list">
<li>Enlicitide compared to placebo (CORALreef HeFH) and other oral non-statin therapies (CORALreef AddOn).</li>
<li>There were no clinically meaningful differences in incidences of adverse events (AE) and serious adverse events (SAE) in either trial.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report" target="_blank" rel="noreferrer noopener">Merck&#8217;s Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report</a>
Results from the three Phase 3 trials in the&nbsp;CORALreef clinical development program&nbsp;will be presented at a future scientific congress.
Key takeaways from CORALreef HeFH and CORALreef AddOn studies:
<ul class="wp-block-list">
<li>CORALreef HeFH: Statistically significant and clinically meaningful reductions in LDL-C for enlicitide versus placebo in adults with heterozygous familial hypercholesterolemia (HeFH) who have a history of or are at risk for atherosclerotic cardiovascular disease (ASCVD) and are treated with a statin.</li>
<li>CORALreef AddOn: Statistically significant and clinically meaningful reductions in LDL-C for enlicitide versus ezetimibe, versus bempedoic acid and versus ezetimibe and bempedoic acid in adults with hyperlipidemia who have a history of or are at risk for ASCVD and are treated with a statin.</li>
</ul>
The efficacy and safety of enlicitide are being evaluated through the comprehensive&nbsp;CORALreef Phase 3 clinical development program, which <a target="_blank" href="https://www.merck.com/wp-content/uploads/sites/124/2025/06/CORALreef_Clinical_Trial_Explainer.pdf" rel="noreferrer noopener">aims</a> to enroll approximately 17,000 patients across several trials, including two large ongoing trials, CORALreef Lipids and CORALreef Outcomes.
Price Action: MRK stock is trading higher by 0.19% to $79.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45841878/analyst-says-newamsterdam-stock-has-over-100-upside-citing-90-success-probability-for-obicetrapib" target="_blank" rel="noreferrer noopener">Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib</a></li>
</ul>
Photo by tada images via Shutterstock

Biotech

Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials

OKLO

Oklo shares are trading higher after Seaport Global upgraded the stock from Neutral to Buy and announced a $71 price target.

Press Releases

Newsweek Names Travel + Leisure Co. Among the Most Trustworthy Companies in America in 2025

FOOD & WINE CLASSIC IN CHARLESTON RETURNS THIS NOVEMBER WITH STAR-STUDDED LINEUP OF CULINARY TALENT

Fins Up, Orlando! Travel + Leisure Co. Announces Plans for New Proposed Margaritaville Vacation Club Location in Central Florida

Travel

WorldMark by Wyndham Hiking Concierge Program Provides National Park Visitors with Expert Tips for Every Adventure Just Beyond the Trailhead

RCI Honors Global Leaders in Sustainable Hospitality with Expanded Green Awards Program

Travel + Leisure Co. Reports First Quarter 2025 Results

Travel + Leisure Co. Appoints Erik Hoag as New Chief Financial Officer Amid Strategic Growth and Brand Portfolio Expansion

Travel + Leisure Co. Declares Cash Dividend

Travel + Leisure Co. Recognized as a 2025-2026 Best Company to Work For by U.S. News & World Report

Travel + Leisure Co. to Present at the Morgan Stanley 3rd Annual Travel & Leisure Conference

Airbnb

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Booking Holdings

Choice Hotels International, Inc. Common Stock

Choice Hotels Intl

Expedia Group

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Gr

Hyatt Hotels Corporation Class A Common Stock

Hyatt Hotels

Hilton Grand Vacations

Hilton Worldwide Holdings Inc. Common Stock

Hilton Worldwide Holdings

H World Group Limited - American Depositary Shares

H World Group

Intercontinental Hotels Group American Depositary Shares (Each representing one Ordinary Share)

Comments

Travel+Leisure

Noticias

Últimas noticias sobre Travel+Leisure (NYSE:TNL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL